{"success":true,"data":{"pressRelease":{"id":"51709","rtpr_id":"nGNX7lghyV","ticker":"CRNX","exchange":"NASDAQ","all_tickers":["CRNX"],"title":"Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations","author":"Globe Newswire","published_at":"2026-06-02T08:55:00.129Z","article_body":"Oral presentation features open label extension PALSONIFY™ (paltusotine)\ndata, reinforcing its best-in-class potential in acromegaly following recent\nU.S. and E.U. approvals \n\nTwo oral presentations of novel, investigational ACTH receptor antagonist\natumelnant include full Phase 2 study results in congenital adrenal\nhyperplasia and data from additional patients in the Phase 1b/2a\nACTH-dependent Cushing’s syndrome study\n\nSAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.\n(https://www.globenewswire.com/Tracker?data=jhRJT6L2x5Pj84mzDieC9ojz_gNNuDxj-7qx81cURINE3ny7q1Dc_Gl2HfRDUEA0H3o9CMZHHXvlPDYP-KzrVc7BrBhSaEolcC6SxRguz80=) (Nasdaq:\nCRNX) today announced that data from six abstracts, including oral\npresentations featuring PALSONIFY™ (paltusotine) and investigational\ncandidate atumelnant, will be presented at the Endocrine Society’s Annual\nMeeting, ENDO 2026, June 13-16, 2026, in Chicago, IL.\n\n\"At ENDO 2026, new data will be presented which increase the depth of clinical\nevidence supporting the long-term safety and efficacy of Palsonify for the\ntreatment of acromegaly,\" said Dr. Alan Krasner, M.D., Chief Endocrinologist,\nCrinetics. “In addition, updated data will be presented characterizing the\npotential of atumelnant to set an uncompromising bar for treating diseases of\nACTH excess. I have often been frustrated by the lack of optimized treatments\nfor these and many other difficult to manage endocrine conditions. At\nCrinetics, we are continuously working with many outstanding external\ninvestigator colleagues to redefine the possibilities.”\n\nThree abstracts will report data related to PALSONIFY in acromegaly, including\nan oral presentation featuring long-term (up to two years) efficacy and pooled\nsafety data from the PATHFNDR-1 and PATHFNDR-2 open-label extension (OLE)\nstudies. Additionally, one poster presentation evaluates real-world\nbiochemical control in acromegaly using U.S. claims and laboratory data to\nidentify areas of unmet need for patients and to inform optimization of\nacromegaly management. Another poster presentation assesses long-term safety\nand efficacy of PALSONIFY in combination with cabergoline from the ACROBAT\nAdvance trial.\n\nThree abstracts from Crinetics’ atumelnant clinical development program will\nalso be presented, including oral presentations of full Phase 2 data in\ncongenital adrenal hyperplasia (CAH) and new interim results from a Phase\n1b/2a study in ACTH-dependent Cushing’s syndrome. An additional rapid-fire\npresentation highlights dose selection data for the Phase 3 trial in CAH.\n\nCrinetics will also present a product theater June 15 from 12:30-1:30 CST,\ntitled “Advancing Acromegaly Management: Bridging Clinical Evidence and the\nPatient Journey with PALSONIFY™ (paltusotine). Presenters include Dr.\nAnthony Heaney and a patient living with acromegaly.\n\nPresentation details are shown below.\n\nPALSONIFY™ (paltusotine) Presentations\n\nTitle (oral presentation): Efficacy and Safety of Once-Daily\nOral Paltusotine in Patients with Acromegaly: Up to 2 years in the\nPATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies \nAuthors: Gadelha, M.R. “et. al.\"\nDate/Time: June 14, 1:45 PM – 3:15 PM CT\nLocation: Room W183BC\n\nTitle (poster presentation): Long-Term Safety and Efficacy of Once-Daily Oral\nPaltusotine in Combination With Cabergoline for the Treatment of\nPatients With Acromegaly \nAuthors: Gadelha. M.R. “et. al.\"\nDate/Time: June 14; 12:00 PM – 1:30 pm CT\nLocation: ENDO Expo Hall, McCormick Place West\n\nTitle (poster presentation): Real-World Biochemical Control in Acromegaly:\nInsights from US Claims and Laboratory Data \nAuthors: Wang, S “et. al.\"\nDate/Time: June 15; 12:00 PM – 1:30 pm CT\nLocation: ENDO Expo Hall, McCormick Place West\n\nAtumelnant Presentations\n\nTitle (oral presentation): Once Daily Atumelnant (CRN04894) Enables Lowering\nof Glucocorticoid Doses With Sustained Androgen Reduction in Adults With\nCongenital Adrenal Hyperplasia \nAuthors: Srirangalingam, U., “et. al.\"\nDate/Time: June 14, 1:45 PM – 3:15 PM CT\nLocation: Room W184ABC\n\nTitle (oral presentation): ‘Block And Replace’ Atumelnant (CRN04894) And\nPhysiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism In\nACTH-dependent Cushing Syndrome\nAuthors: Elenius, H., “et al”\nDate/Time: June 14, 3:30 PM – 4:15 PM CT\nLocation: Room W187\n\nTitle (rapid-fire and poster presentations): Model-Informed Atumelnant Dose\nSelection for a Phase 3 Study in Adult Patients With Classic Congenital\nAdrenal Hyperplasia \nAuthors: Curd, L., “et. al.\" \nDates/Times: Rapid Fire: June 14, 1:45 PM - 3:15 PM CT\n                        Poster: June 15, 12:00 PM – 1:30 PM CT\nLocations: Rapid Fire: Room W184ABC\n                    Poster: ENDO Expo Hall, McCormick Place West\n\nAbout PALSONIFY™ (Paltusotine)\nPALSONIFY, a selectively-targeted somatostatin receptor type 2 (SST2)\nnonpeptide agonist, is the first and only once-daily, oral therapy approved\nfor the treatment of adults with acromegaly who had an inadequate response to\nsurgery and/or for whom surgery is not an option. In Phase 3 studies,\nonce-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in\npatients with acromegaly who were switched from monthly injectable medications\n(PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in\nmedically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary\nbiomarker endocrinologists use to manage acromegaly patients. Paltusotine is\nalso in Phase 3 clinical development for carcinoid syndrome associated with\nneuroendocrine tumors (CAREFNDR). Results from a Phase 2 study in carcinoid\nsyndrome demonstrated rapid and sustained reductions in flushing episodes and\nbowel movement frequency, which are the most common symptoms of carcinoid\nsyndrome.\nPALSONIFY is approved in the U.S. for the first-line treatment of adults with\nacromegaly who had an inadequate response to surgery and/or for whom surgery\nis not an option. It is also approved for use in the EU for the medical\ntreatment of adult patients with acromegaly.\n\nAbout Atumelnant\nAtumelnant, Crinetics’ second investigational compound, is the first\nonce-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that\nacts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal\ngland. Diseases associated with excess ACTH can have significant impact on\nphysical and mental health. Atumelnant has exhibited strong binding affinity\nfor MC2R in preclinical models and has demonstrated suppression of adrenally\nderived glucocorticoids and androgens that are under the control of ACTH. Data\nfrom a 12-week Phase 2 study demonstrated compelling treatment benefits of\natumelnant, evidenced by the rapid, substantial and sustained statistically\nsignificant reductions in key CAH disease related biomarkers, including\nandrostenedione and 17-hydroxyprogesterone, in a diverse population.\nAtumelnant is in development for congenital adrenal hyperplasia and\nACTH-dependent Cushing’s syndrome, with the Phase 3 CALM-CAH trial and a\nPhase 1/2b trial in ADCS currently enrolling patients.\n\nAbout Crinetics Pharmaceuticals  \nCrinetics Pharmaceuticals is a global pharmaceutical company committed to\ntransforming the treatment of endocrine diseases and endocrine-related tumors\nthrough science rooted in patient needs. Crinetics is focused on discovering,\ndeveloping, and commercializing novel therapies, with a core expertise in\ntargeting G-protein coupled receptors (GPCRs) with small molecules that have\nspecifically tailored pharmacology and properties.\n\nCrinetics’ first commercial product, PALSONIFY™ (paltusotine), is the\nfirst once-daily, oral treatment approved by the U.S. FDA and EMA for the\ntreatment of adults with acromegaly who had an inadequate response to surgery\nand/or for whom surgery is not an option. Paltusotine is also in clinical\ndevelopment for carcinoid syndrome associated with neuroendocrine tumors.\nCrinetics’ deep pipeline of 10+ disclosed programs includes late-stage\ninvestigational candidate atumelnant, which is currently in development for\ncongenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and\nCRN09682, a nonpeptide drug conjugate candidate that is being developed to\ntreat somatostatin receptor 2 (SST2) expressing neuroendocrine tumors and\nother SST2 expressing solid tumors. Additional discovery programs are focused\non a variety of endocrine targets such as thyroid stimulating hormone (TSH),\nparathyroid hormone (PTH), somatostatin receptor 3 (SST3), growth hormone\n(GH), glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic\npolypeptide (GIP), as well as GPCR-targeted oncology indications.\n\nPALSONIFY™ (paltusotine) INDICATION:\nPALSONIFY is a somatostatin receptor agonist indicated for the treatment of\nadults with acromegaly who had an inadequate response to surgery and/or for\nwhom surgery is not an option.\n\nIMPORTANT SAFETY INFORMATION\nWARNINGS AND PRECAUTIONS:\n* Cholelithiasis and Its Complications: Cholelithiasis, including related\ncomplications such as acute cholecystitis and pancreatitis, have been\nreported. Monitor patients periodically. Discontinue PALSONIFY if\ncomplications of cholelithiasis occur and treat appropriately.\n* Hyperglycemia and Hypoglycemia: Hyperglycemia, diabetes mellitus, or\nhypoglycemia, may occur. Monitor blood glucose levels when PALSONIFY treatment\nis initiated or when dosage is altered. Adjust antidiabetic treatment\naccordingly.\n* Cardiovascular Abnormalities: Cardiac conduction abnormalities and other\nECG changes such as PR interval prolongation, bradycardia, sinus arrest, and\natrioventricular block may occur in patients with acromegaly and were reported\nin PALSONIFY clinical trials. Dosage adjustments of concomitant drugs that\nhave bradycardic effects may be necessary.\n* Thyroid Function Abnormalities: Somatostatin analogs may suppress the\nsecretion of thyroid-stimulating hormone, which may result in hypothyroidism.\nPeriodic assessment of thyroid function is recommended.\n* Steatorrhea and Malabsorption of Dietary Fats: Somatostatin analog\ntreatment may result in malabsorption of dietary fats and subsequent symptoms\nof steatorrhea, loose stools, abdominal bloating, and weight loss. If new or\nworsening symptoms are reported with PALSONIFY, evaluate patients for\npotential pancreatic exocrine insufficiency and manage accordingly.\n* Vitamin B12 Deficiency: Vitamin B12 deficiency may occur. Monitor vitamin\nB12 levels, if clinically indicated.\nADVERSE REACTIONS:\nMost common adverse reactions (>5%) are diarrhea, abdominal pain, nausea,\ndecreased appetite, sinus bradycardia, hyperglycemia, palpitations, and\ngastroenteritis.\n\nDRUG INTERACTIONS:\n* Strong or Moderate CYP3A4 Inducers: may decrease PALSONIFY exposure. May\nrequire an increased dosage of PALSONIFY.\n* Proton Pump Inhibitors: may decrease PALSONIFY exposure. May require an\nincreased dosage of PALSONIFY. Avoid concomitant use of proton pump inhibitors\nin patients who are already on PALSONIFY 60 mg.\n* Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine\ndosage adjustment when used with PALSONIFY; follow therapeutic monitoring\nrecommendations.\nPlease report adverse events to Crinetics Pharmaceuticals at 1-833-CRN-INFO\n(1-833-276-4636) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPlease see Full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=GuQle_vsaIcCjr31heITYcXxQggqpsk4iK-ekNl_mi8okd2Q-fX7L79ZxflapCVzWHoSoH0ra11EmP8e2vCdCklM_3BgoBdO8777KK6yazyrRiWZVgw6wM9ZGnqxVin3) including Patient\nInformation\n(https://www.globenewswire.com/Tracker?data=s3JU8D33yxJlU__IefEJOCTckBVHYYf7dGvNUW8mVY7RGa1LueFAjhRQvWnltfqvRiWO4aFAJ-E1rkVOl5j5B-Px8f8--ZoBxKFqwLoTDLohWhdtsvg-YmxjgH5w30A-EmW0Rz864PWkBkHQvxGJtQ==).\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. All statements other than\nstatements of historical facts contained in this press release are\nforward-looking statements, including statements regarding the plans and\ntimelines for the clinical development of atumelnant and paltusotine for the\ntreatment of carcinoid syndrome; or the potential for our development\ncandidates to transition to clinical development. In some cases, you can\nidentify forward-looking statements by terms such as “may,” “will,”\n“should,” “expect,” “plan,” “anticipate,” “could,”\n“intend,” “target,” “project,” “contemplates,” “believes,”\n“estimates,” “predicts,” “potential,” “upcoming” or\n“continue” or the negative of these terms or other similar expressions.\nThese forward-looking statements speak only as of the date of this press\nrelease and are subject to a number of risks, uncertainties and assumptions,\nincluding, without limitation, we may not be able to obtain, maintain and\nenforce our patents and other intellectual property rights, and it may be\nprohibitively difficult or costly to protect such rights; geopolitical events\nmay disrupt Crinetics’ business and that of the third parties on which it\ndepends, including delaying or otherwise disrupting clinical studies and\npreclinical studies, manufacturing and supply chain, or impairing employee\nproductivity; unexpected adverse side effects, complications and/or drug\ninteractions or inadequate efficacy of the Company’s product candidates that\nmay limit their development, regulatory approval and/or commercialization; the\nCompany’s dependence on third parties in connection with product\nmanufacturing, research and preclinical and clinical testing; regulatory\ndevelopments or political changes, including policies related to pricing and\npharmaceutical drug reimbursement, in the United States and foreign countries;\nthe timing and outcome of research, development and regulatory review is\nuncertain, and Crinetics’ drug candidates may not advance in development or\nbe approved for marketing; Crinetics may use its capital resources sooner than\nexpected or our cash burn rate may accelerate; any future impacts to our\nbusiness resulting from geopolitical developments outside our control; and the\nother risks and uncertainties described in the Company’s periodic filings\nwith the Securities and Exchange Commission (SEC). The events and\ncircumstances reflected in the company’s forward-looking statements may not\nbe achieved or occur and actual results could differ materially from those\nprojected in the forward-looking statements. Additional information on risks\nfacing Crinetics can be found under the heading “Risk Factors” in\nCrinetics’ periodic filings with the SEC, including its annual report on\nForm 10-K for the year ended December 31, 2025. You are cautioned not to place\nundue reliance on these forward-looking statements, which speak only as of the\ndate hereof. Except as required by applicable law, Crinetics does not plan to\npublicly update or revise any forward-looking statements contained herein,\nwhether as a result of any new information, future events, changed\ncircumstances or otherwise.\n\nMedia:\nNatalie Badillo\nHead of Corporate Communications\nnbadillo@crinetics.com\n(858) 345-6075\n\nInvestors:\nGyathri Diwakar\nHead of Investor Relations\ngdiwakar@crinetics.com\n(858) 345-6340\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ff5e7cfa-b9fb-4679-8bf3-6e9d25207b83)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7lghyV","title":"Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations","author":"Globe Newswire","ticker":"CRNX","created":"2026-06-02T08:55:00.129Z","tickers":["CRNX"],"exchange":"NASDAQ","article_body":"Oral presentation features open label extension PALSONIFY™ (paltusotine)\ndata, reinforcing its best-in-class potential in acromegaly following recent\nU.S. and E.U. approvals \n\nTwo oral presentations of novel, investigational ACTH receptor antagonist\natumelnant include full Phase 2 study results in congenital adrenal\nhyperplasia and data from additional patients in the Phase 1b/2a\nACTH-dependent Cushing’s syndrome study\n\nSAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.\n(https://www.globenewswire.com/Tracker?data=jhRJT6L2x5Pj84mzDieC9ojz_gNNuDxj-7qx81cURINE3ny7q1Dc_Gl2HfRDUEA0H3o9CMZHHXvlPDYP-KzrVc7BrBhSaEolcC6SxRguz80=) (Nasdaq:\nCRNX) today announced that data from six abstracts, including oral\npresentations featuring PALSONIFY™ (paltusotine) and investigational\ncandidate atumelnant, will be presented at the Endocrine Society’s Annual\nMeeting, ENDO 2026, June 13-16, 2026, in Chicago, IL.\n\n\"At ENDO 2026, new data will be presented which increase the depth of clinical\nevidence supporting the long-term safety and efficacy of Palsonify for the\ntreatment of acromegaly,\" said Dr. Alan Krasner, M.D., Chief Endocrinologist,\nCrinetics. “In addition, updated data will be presented characterizing the\npotential of atumelnant to set an uncompromising bar for treating diseases of\nACTH excess. I have often been frustrated by the lack of optimized treatments\nfor these and many other difficult to manage endocrine conditions. At\nCrinetics, we are continuously working with many outstanding external\ninvestigator colleagues to redefine the possibilities.”\n\nThree abstracts will report data related to PALSONIFY in acromegaly, including\nan oral presentation featuring long-term (up to two years) efficacy and pooled\nsafety data from the PATHFNDR-1 and PATHFNDR-2 open-label extension (OLE)\nstudies. Additionally, one poster presentation evaluates real-world\nbiochemical control in acromegaly using U.S. claims and laboratory data to\nidentify areas of unmet need for patients and to inform optimization of\nacromegaly management. Another poster presentation assesses long-term safety\nand efficacy of PALSONIFY in combination with cabergoline from the ACROBAT\nAdvance trial.\n\nThree abstracts from Crinetics’ atumelnant clinical development program will\nalso be presented, including oral presentations of full Phase 2 data in\ncongenital adrenal hyperplasia (CAH) and new interim results from a Phase\n1b/2a study in ACTH-dependent Cushing’s syndrome. An additional rapid-fire\npresentation highlights dose selection data for the Phase 3 trial in CAH.\n\nCrinetics will also present a product theater June 15 from 12:30-1:30 CST,\ntitled “Advancing Acromegaly Management: Bridging Clinical Evidence and the\nPatient Journey with PALSONIFY™ (paltusotine). Presenters include Dr.\nAnthony Heaney and a patient living with acromegaly.\n\nPresentation details are shown below.\n\nPALSONIFY™ (paltusotine) Presentations\n\nTitle (oral presentation): Efficacy and Safety of Once-Daily\nOral Paltusotine in Patients with Acromegaly: Up to 2 years in the\nPATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies \nAuthors: Gadelha, M.R. “et. al.\"\nDate/Time: June 14, 1:45 PM – 3:15 PM CT\nLocation: Room W183BC\n\nTitle (poster presentation): Long-Term Safety and Efficacy of Once-Daily Oral\nPaltusotine in Combination With Cabergoline for the Treatment of\nPatients With Acromegaly \nAuthors: Gadelha. M.R. “et. al.\"\nDate/Time: June 14; 12:00 PM – 1:30 pm CT\nLocation: ENDO Expo Hall, McCormick Place West\n\nTitle (poster presentation): Real-World Biochemical Control in Acromegaly:\nInsights from US Claims and Laboratory Data \nAuthors: Wang, S “et. al.\"\nDate/Time: June 15; 12:00 PM – 1:30 pm CT\nLocation: ENDO Expo Hall, McCormick Place West\n\nAtumelnant Presentations\n\nTitle (oral presentation): Once Daily Atumelnant (CRN04894) Enables Lowering\nof Glucocorticoid Doses With Sustained Androgen Reduction in Adults With\nCongenital Adrenal Hyperplasia \nAuthors: Srirangalingam, U., “et. al.\"\nDate/Time: June 14, 1:45 PM – 3:15 PM CT\nLocation: Room W184ABC\n\nTitle (oral presentation): ‘Block And Replace’ Atumelnant (CRN04894) And\nPhysiologic Hydrocortisone Replacement Rapidly Controls Hypercortisolism In\nACTH-dependent Cushing Syndrome\nAuthors: Elenius, H., “et al”\nDate/Time: June 14, 3:30 PM – 4:15 PM CT\nLocation: Room W187\n\nTitle (rapid-fire and poster presentations): Model-Informed Atumelnant Dose\nSelection for a Phase 3 Study in Adult Patients With Classic Congenital\nAdrenal Hyperplasia \nAuthors: Curd, L., “et. al.\" \nDates/Times: Rapid Fire: June 14, 1:45 PM - 3:15 PM CT\n                        Poster: June 15, 12:00 PM – 1:30 PM CT\nLocations: Rapid Fire: Room W184ABC\n                    Poster: ENDO Expo Hall, McCormick Place West\n\nAbout PALSONIFY™ (Paltusotine)\nPALSONIFY, a selectively-targeted somatostatin receptor type 2 (SST2)\nnonpeptide agonist, is the first and only once-daily, oral therapy approved\nfor the treatment of adults with acromegaly who had an inadequate response to\nsurgery and/or for whom surgery is not an option. In Phase 3 studies,\nonce-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in\npatients with acromegaly who were switched from monthly injectable medications\n(PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in\nmedically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary\nbiomarker endocrinologists use to manage acromegaly patients. Paltusotine is\nalso in Phase 3 clinical development for carcinoid syndrome associated with\nneuroendocrine tumors (CAREFNDR). Results from a Phase 2 study in carcinoid\nsyndrome demonstrated rapid and sustained reductions in flushing episodes and\nbowel movement frequency, which are the most common symptoms of carcinoid\nsyndrome.\nPALSONIFY is approved in the U.S. for the first-line treatment of adults with\nacromegaly who had an inadequate response to surgery and/or for whom surgery\nis not an option. It is also approved for use in the EU for the medical\ntreatment of adult patients with acromegaly.\n\nAbout Atumelnant\nAtumelnant, Crinetics’ second investigational compound, is the first\nonce-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that\nacts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal\ngland. Diseases associated with excess ACTH can have significant impact on\nphysical and mental health. Atumelnant has exhibited strong binding affinity\nfor MC2R in preclinical models and has demonstrated suppression of adrenally\nderived glucocorticoids and androgens that are under the control of ACTH. Data\nfrom a 12-week Phase 2 study demonstrated compelling treatment benefits of\natumelnant, evidenced by the rapid, substantial and sustained statistically\nsignificant reductions in key CAH disease related biomarkers, including\nandrostenedione and 17-hydroxyprogesterone, in a diverse population.\nAtumelnant is in development for congenital adrenal hyperplasia and\nACTH-dependent Cushing’s syndrome, with the Phase 3 CALM-CAH trial and a\nPhase 1/2b trial in ADCS currently enrolling patients.\n\nAbout Crinetics Pharmaceuticals  \nCrinetics Pharmaceuticals is a global pharmaceutical company committed to\ntransforming the treatment of endocrine diseases and endocrine-related tumors\nthrough science rooted in patient needs. Crinetics is focused on discovering,\ndeveloping, and commercializing novel therapies, with a core expertise in\ntargeting G-protein coupled receptors (GPCRs) with small molecules that have\nspecifically tailored pharmacology and properties.\n\nCrinetics’ first commercial product, PALSONIFY™ (paltusotine), is the\nfirst once-daily, oral treatment approved by the U.S. FDA and EMA for the\ntreatment of adults with acromegaly who had an inadequate response to surgery\nand/or for whom surgery is not an option. Paltusotine is also in clinical\ndevelopment for carcinoid syndrome associated with neuroendocrine tumors.\nCrinetics’ deep pipeline of 10+ disclosed programs includes late-stage\ninvestigational candidate atumelnant, which is currently in development for\ncongenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and\nCRN09682, a nonpeptide drug conjugate candidate that is being developed to\ntreat somatostatin receptor 2 (SST2) expressing neuroendocrine tumors and\nother SST2 expressing solid tumors. Additional discovery programs are focused\non a variety of endocrine targets such as thyroid stimulating hormone (TSH),\nparathyroid hormone (PTH), somatostatin receptor 3 (SST3), growth hormone\n(GH), glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic\npolypeptide (GIP), as well as GPCR-targeted oncology indications.\n\nPALSONIFY™ (paltusotine) INDICATION:\nPALSONIFY is a somatostatin receptor agonist indicated for the treatment of\nadults with acromegaly who had an inadequate response to surgery and/or for\nwhom surgery is not an option.\n\nIMPORTANT SAFETY INFORMATION\nWARNINGS AND PRECAUTIONS:\n* Cholelithiasis and Its Complications: Cholelithiasis, including related\ncomplications such as acute cholecystitis and pancreatitis, have been\nreported. Monitor patients periodically. Discontinue PALSONIFY if\ncomplications of cholelithiasis occur and treat appropriately.\n* Hyperglycemia and Hypoglycemia: Hyperglycemia, diabetes mellitus, or\nhypoglycemia, may occur. Monitor blood glucose levels when PALSONIFY treatment\nis initiated or when dosage is altered. Adjust antidiabetic treatment\naccordingly.\n* Cardiovascular Abnormalities: Cardiac conduction abnormalities and other\nECG changes such as PR interval prolongation, bradycardia, sinus arrest, and\natrioventricular block may occur in patients with acromegaly and were reported\nin PALSONIFY clinical trials. Dosage adjustments of concomitant drugs that\nhave bradycardic effects may be necessary.\n* Thyroid Function Abnormalities: Somatostatin analogs may suppress the\nsecretion of thyroid-stimulating hormone, which may result in hypothyroidism.\nPeriodic assessment of thyroid function is recommended.\n* Steatorrhea and Malabsorption of Dietary Fats: Somatostatin analog\ntreatment may result in malabsorption of dietary fats and subsequent symptoms\nof steatorrhea, loose stools, abdominal bloating, and weight loss. If new or\nworsening symptoms are reported with PALSONIFY, evaluate patients for\npotential pancreatic exocrine insufficiency and manage accordingly.\n* Vitamin B12 Deficiency: Vitamin B12 deficiency may occur. Monitor vitamin\nB12 levels, if clinically indicated.\nADVERSE REACTIONS:\nMost common adverse reactions (>5%) are diarrhea, abdominal pain, nausea,\ndecreased appetite, sinus bradycardia, hyperglycemia, palpitations, and\ngastroenteritis.\n\nDRUG INTERACTIONS:\n* Strong or Moderate CYP3A4 Inducers: may decrease PALSONIFY exposure. May\nrequire an increased dosage of PALSONIFY.\n* Proton Pump Inhibitors: may decrease PALSONIFY exposure. May require an\nincreased dosage of PALSONIFY. Avoid concomitant use of proton pump inhibitors\nin patients who are already on PALSONIFY 60 mg.\n* Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine\ndosage adjustment when used with PALSONIFY; follow therapeutic monitoring\nrecommendations.\nPlease report adverse events to Crinetics Pharmaceuticals at 1-833-CRN-INFO\n(1-833-276-4636) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.\nPlease see Full Prescribing Information\n(https://www.globenewswire.com/Tracker?data=GuQle_vsaIcCjr31heITYcXxQggqpsk4iK-ekNl_mi8okd2Q-fX7L79ZxflapCVzWHoSoH0ra11EmP8e2vCdCklM_3BgoBdO8777KK6yazyrRiWZVgw6wM9ZGnqxVin3) including Patient\nInformation\n(https://www.globenewswire.com/Tracker?data=s3JU8D33yxJlU__IefEJOCTckBVHYYf7dGvNUW8mVY7RGa1LueFAjhRQvWnltfqvRiWO4aFAJ-E1rkVOl5j5B-Px8f8--ZoBxKFqwLoTDLohWhdtsvg-YmxjgH5w30A-EmW0Rz864PWkBkHQvxGJtQ==).\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. All statements other than\nstatements of historical facts contained in this press release are\nforward-looking statements, including statements regarding the plans and\ntimelines for the clinical development of atumelnant and paltusotine for the\ntreatment of carcinoid syndrome; or the potential for our development\ncandidates to transition to clinical development. In some cases, you can\nidentify forward-looking statements by terms such as “may,” “will,”\n“should,” “expect,” “plan,” “anticipate,” “could,”\n“intend,” “target,” “project,” “contemplates,” “believes,”\n“estimates,” “predicts,” “potential,” “upcoming” or\n“continue” or the negative of these terms or other similar expressions.\nThese forward-looking statements speak only as of the date of this press\nrelease and are subject to a number of risks, uncertainties and assumptions,\nincluding, without limitation, we may not be able to obtain, maintain and\nenforce our patents and other intellectual property rights, and it may be\nprohibitively difficult or costly to protect such rights; geopolitical events\nmay disrupt Crinetics’ business and that of the third parties on which it\ndepends, including delaying or otherwise disrupting clinical studies and\npreclinical studies, manufacturing and supply chain, or impairing employee\nproductivity; unexpected adverse side effects, complications and/or drug\ninteractions or inadequate efficacy of the Company’s product candidates that\nmay limit their development, regulatory approval and/or commercialization; the\nCompany’s dependence on third parties in connection with product\nmanufacturing, research and preclinical and clinical testing; regulatory\ndevelopments or political changes, including policies related to pricing and\npharmaceutical drug reimbursement, in the United States and foreign countries;\nthe timing and outcome of research, development and regulatory review is\nuncertain, and Crinetics’ drug candidates may not advance in development or\nbe approved for marketing; Crinetics may use its capital resources sooner than\nexpected or our cash burn rate may accelerate; any future impacts to our\nbusiness resulting from geopolitical developments outside our control; and the\nother risks and uncertainties described in the Company’s periodic filings\nwith the Securities and Exchange Commission (SEC). The events and\ncircumstances reflected in the company’s forward-looking statements may not\nbe achieved or occur and actual results could differ materially from those\nprojected in the forward-looking statements. Additional information on risks\nfacing Crinetics can be found under the heading “Risk Factors” in\nCrinetics’ periodic filings with the SEC, including its annual report on\nForm 10-K for the year ended December 31, 2025. You are cautioned not to place\nundue reliance on these forward-looking statements, which speak only as of the\ndate hereof. Except as required by applicable law, Crinetics does not plan to\npublicly update or revise any forward-looking statements contained herein,\nwhether as a result of any new information, future events, changed\ncircumstances or otherwise.\n\nMedia:\nNatalie Badillo\nHead of Corporate Communications\nnbadillo@crinetics.com\n(858) 345-6075\n\nInvestors:\nGyathri Diwakar\nHead of Investor Relations\ngdiwakar@crinetics.com\n(858) 345-6340\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ff5e7cfa-b9fb-4679-8bf3-6e9d25207b83)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-02T08:55:00.171730284Z","server_sent_at_ms":1780390500171},"received_at":"2026-06-02T08:55:00.327Z","source_url":null},"analysis":{"id":"41142","press_release_id":"51709","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"Crinetics Pharmaceuticals will present six abstracts at ENDO 2026, including three oral presentations highlighting its approved drug PALSONIFY and investigational candidate atumelnant.\n\nPALSONIFY data includes long-term efficacy and pooled safety from open-label extension studies in acromegaly, reinforcing its best-in-class profile following recent U.S. and E.U. approvals.\n\nAtumelnant presentations feature full Phase 2 results in congenital adrenal hyperplasia and interim data from a Phase 1b/2a study in ACTH-dependent Cushing’s syndrome, supporting upcoming Phase 3 dose selection.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Crinetics reinforces pipeline strength with 6 ENDO 2026 presentations, including positive long-term data for approved PALSONIFY and promising Phase 2 results for atumelnant."},"keyFigures":{"drugName":"PALSONIFY (paltusotine), atumelnant","phaseOfTrial":"Phase 2 (atumelnant in CAH), Phase 1b/2a (atumelnant in Cushing's)","customDimensions":{"oral_presentations":3,"presentation_count":6,"palsonify_ole_duration":"up to 2 years"}},"quotedText":"At ENDO 2026, new data will be presented which increase the depth of clinical evidence supporting the long-term safety and efficacy of Palsonify for the treatment of acromegaly","namedEntities":{"people":[{"name":"Dr. Alan Krasner","role":"Chief Endocrinologist"},{"name":"Dr. Anthony Heaney","role":"Presenter"},{"name":"Natalie Badillo","role":"Head of Corporate Communications"},{"name":"Gyathri Diwakar","role":"Head of Investor Relations"}],"products":["PALSONIFY","paltusotine","atumelnant","CRN04894","CRN09682","cabergoline"],"companies":[{"name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX"},{"name":"Endocrine Society","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Presentation of positive long-term safety/efficacy data for approved drug PALSONIFY and promising Phase 2/interim data for late-stage pipeline asset atumelnant at a major industry conference. No binary regulatory decision, but reinforces development trajectory."},"tickerRelevance":{"others":[],"primary":"CRNX"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"clinical_data_presentation","sectorWeight":"high","householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Crinetics Pharmaceuticals will present six abstracts at ENDO 2026, including three oral presentations highlighting its approved drug PALSONIFY and investigational candidate atumelnant.\n\nPALSONIFY data includes long-term efficacy and pooled safety from open-label extension studies in acromegaly, reinforcing its best-in-class profile following recent U.S. and E.U. approvals.\n\nAtumelnant presentations feature full Phase 2 results in congenital adrenal hyperplasia and interim data from a Phase 1b/2a study in ACTH-dependent Cushing’s syndrome, supporting upcoming Phase 3 dose selection.","key_figures":{"drugName":"PALSONIFY (paltusotine), atumelnant","phaseOfTrial":"Phase 2 (atumelnant in CAH), Phase 1b/2a (atumelnant in Cushing's)","customDimensions":{"oral_presentations":3,"presentation_count":6,"palsonify_ole_duration":"up to 2 years"}},"named_entities":{"people":[{"name":"Dr. Alan Krasner","role":"Chief Endocrinologist"},{"name":"Dr. Anthony Heaney","role":"Presenter"},{"name":"Natalie Badillo","role":"Head of Corporate Communications"},{"name":"Gyathri Diwakar","role":"Head of Investor Relations"}],"products":["PALSONIFY","paltusotine","atumelnant","CRN04894","CRN09682","cabergoline"],"companies":[{"name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX"},{"name":"Endocrine Society","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T08:55:35.261Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap","eventGravity":"clinical_data_presentation","sectorWeight":"high","householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":34901,"modelName":"george-droid-qwen-72b"}}